Capricor Therapeutics Q3 net loss widens as expenses rise

By Reuters News


Overview

  • US biotech reported no Q3 revenue as focus remained on late-stage therapy development

  • Q3 operating expenses rose yr/yr, mainly due to pre-commercial and manufacturing scale-up

  • Net loss widened in Q3 2026 compared to prior year


Outlook

  • Company expects cash resources to fund operations for at least the next 12 months

  • Capricor to provide further financial guidance after regulatory clarity on Deramiocel

  • Company's outlook excludes potential revenue from product sales or Priority Review Voucher monetization


Result Drivers

  • PRE-COMMERCIAL SPENDING - Higher Q3 operating expenses were primarily driven by pre-commercial activities and manufacturing scale-up

  • WORKFORCE REDUCTION - Co implemented a workforce reduction in Q3, affecting about 10% of employees to reduce operating expenses and align resources with priorities


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.73

Q3 Net Loss

$42.70 mln

Q3 Loss Per Basic Share

$0.73

Q3 Operating Expenses

$44.70 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Capricor Therapeutics, Inc. is $18.50, about 87.8% above its November 9 closing price of $9.85


Reuters Recommended Reads

  • Nov 10 - Tyra Biosciences Q3 net loss widens on higher R&D costs

  • Nov 10 - Corbus Pharmaceuticals Q3 net loss widens on higher expenses

  • Nov 10 - Biotech firm PepGen's Q3 net loss widens as R&D expenses rise


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk